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Myeloproliferative neoplasms (MPNs) are clonal hematological diseases in which cells of the 
myelo-erythroid lineage are overproduced and patients are predisposed to leukemic 
transformation. Hematopoietic stem cells (HSCs) are the suspected disease initiating cells and 
these cells must acquire a clonal advantage relative to non-mutant HSCs in order to perpetuate 
disease. In 2005, several groups identified a single gain-of-function point mutation in JAK2 that 
associated with the majority of MPNs, and subsequent studies have led to a comprehensive 
understanding of the mutational landscape in MPNs. However, confusion still exists as to how a 
single genetic aberration can be associated with multiple distinct disease entities. Many 
explanations have been proposed, including JAK2V617F homozygosity, individual patient 
heterogeneity and the differential regulation of downstream JAK2 signaling pathways. Several 
groups have made knock-in mouse models expressing JAK2V617F and have observed divergent 
phenotypes, each recapitulating some aspects of disease. Intriguingly, most of these models do 
not observe a strong HSC self-renewal advantage compared to WT littermate controls, raising 
the question of how a clonal advantage is established in MPN patients. This review summarizes 
the current molecular understanding of MPNs, the diversity of disease phenotypes and proposes 
that the increased proliferation induced by JAK2V617F applies a selection pressure on the 





Multipotent hematopoietic stem cells (HSCs) are a rare subpopulation of cells in the bone 
marrow that sit atop a complex and tightly controlled hierarchical production process that 
eventually leads to the formation of all types of mature blood cells [1]. In order to maintain a 
homeostatic balance, a given HSC must on average produce one daughter cell that contributes to 
active hematopoiesis and another daughter cell that retains the HSC maintenance capacity of the 
parent cell [2]. Perturbations in a single HSC that drive an amplification or depletion of 
particular mature blood cell types can typically be tolerated unless that HSC also acquires a 
clonal advantage [3, 4]. 
The concept of heterogeneity in HSCs, and indeed cancers in general, has emerged in the context 
of the enormous genomic knowledge gathered in recent years and therefore it is important to 
consider the molecular pathogenesis of disease from a cell biological perspective. This review 
will detail the process of stem cell subversion through the lens of the myeloproliferative 
neoplasms, a set of chronic, clonal disorders that are an excellent model system for studying 
cancer progression.  
HSC heterogeneity  
Even in the earliest stages of studies in HSC biology, marked heterogeneity in self-renewal of 
pluripotent hematopoietic cells was observed [5, 6]. More recently, differences in proliferation, 
cell cycle status, self-renewal durability and the types of mature cells produced have all been 
uncovered (reviewed in [7]). These aspects could be explained by diverse intrinsically 
determined, (epi-)genetic differentiation programs of individual stem cells [8], by variances in 
the stem cell microenvironment [9] or by an HSC organizational structure governed by stochastic 
fate choices [10]. Recently, single cell transplantation studies of highly purified HSC populations 
revealed variability in white blood cell output and self-renewal durability, identifying at least 
four distinct HSC subtypes, only two of which displayed durable self-renewal properties [11]. 
The first of these showed a relative deficiency in lymphoid cells and the latter displayed a 
balanced proportion of mature cell production. Importantly, secondary transplantation studies 
using clonally derived bone marrow suspensions or single purified HSCs showed highly similar 
repopulation patterns, suggesting that distinct HSC characteristics are intrinsically determined 
[11, 12]. These studies were further bolstered by the prospective enrichment of lineage biased 
HSC subtypes using alternative flow cytometric isolation strategies [13-16]. Even more recently, 
a reclassification of HSC subtypes has been proposed based on reconstitution time periods [17]. 
Tumor heterogeneity  
Genetic, morphologic, phenotypic, clinical, and cell surface marker heterogeneity has been 
observed amongst cells from patients with both solid tumors and hematological malignancies 
(i.e., inter-tumor variation) [18-21]. Most recently, clonal heterogeneity has been also observed 
within a tumor from a single patient (i.e., intra-tumor variation) [18, 20, 22, 23]. Traditionally, 
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two  main  theories  have  been  proposed  to  explain  tumor  heterogeneity.  The  first,  the  “stochastic  
model”,   suggests   that all cells in the clonal hierarchy are equally susceptible to malignant 
transformation. Such tumor cells would be biologically equivalent but would behave variably 
due to further genetic, epigenetic, or environmental changes. Heterogeneity would thus be 
explained by the existence of multiple cells within a tumor possessing the ability to drive a 
malignant clone [24].  The  second,  the  “hierarchical  model”,  suggests  that  tumorigenic  mutations  
only occur in primitive cells (or drive differentiated cells backwards to the primitive state) and 
cause malignancy through an aberrant differentiation cascade. In this model, cancer stem cells 
(CSCs) are biologically distinct from other tumor cells and are the only ones that can give rise to 
a new tumor (also referred to as a tumor initiating cell). Evidence for this latter theory is 
strongest in acute leukemias, where a rare subpopulation of CSCs is present at the apex of the 
clonal hierarchy (reviewed in [25]). Since stem cells persist for a long period of time there is a 
greater opportunity for mutations to accumulate in these cells compared to short-lived mature 
cells and fewer mutations would be required to maintain self-renewal [26]. Recently, it has been 
suggested that genetic diversity, epigenetic modifications and the tumor microenvironment can, 
together or separately, influence stemness and thereby influence tumor progression [27]. As a 
result of acquiring advantageous mutations, several malignant subclones could be established. In 
some clones, there would be a strict hierarchy in which only a few CSCs would exist, whereas in 
other clones the majority of cells would retain self-renew properties, thereby eliminating the 
hierarchical component of the tumor.  
Hierarchical cancer stem cell model in hematological malignancies  
The suggestion that malignant clones mimic normal cell biology was accompanied by the 
supposition that CSCs represented a rare subpopulation of stem cells. Subsequent evidence in 
melanoma [28] and glioblastoma [29] has   challenged   this   theory’s   applicability   to   all   cancers.  
Moreover, no strong consensus exists about the rarity of tumor initiating cells, since higher 
frequencies of cells that are capable to drive tumor growth have been found in various lymphoma 
and leukemia transgenic mouse models [30]. However, many cancers have substantial evidence 
of a cancer stem cell model, including breast cancer [31], brain cancers [32, 33] and colon cancer 
[34, 35]. In myeloid malignancies, CSCs are suggested to be responsible for relapse following 
therapy that removes the bulk tumor but spares the tumor initiating CSCs [36, 37]. While the 
CSC concept cannot be universally applied, a substantial amount of tumor types are associated 
with a hierarchical organization (reviewed in [3]).  
Myeloproliferative neoplasms as a model to track clonal evolution 
Myeloproliferative neoplasms (MPNs) are clonal hematological diseases in which cells of the 
myelo-erythroid lineage are overproduced. They include both BCR-ABL positive chronic 
myelogenous leukemia (CML) as well as the three classical, BCR-ABL negative MPNs known 
as polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) (reviewed 
in [38]). MPNs have been shown to derive from the outgrowth of a single HSC or early myeloid 
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progenitor that acquires somatic mutation(s) [39-41]. Mutant cells clonally expand as the result 
of developing a hypersensitivity to, or independence from, cytokines that regulate proliferation, 
differentiation and/or survival. Formal evidence for an acquired genetic lesion in BCR-ABL 
negative MPNs came in 2005, when several research groups discovered a single point mutation 
in JAK2, called JAK2V617F, which associated with the vast majority of PVs, ETs and MFs [42-
45]. Subsequent discoveries in non-JAK2V617F MPNs identified somatic mutations in JAK2 
exon 12 in PV patients [46, 47], activating mutations of the thrombopoietin receptor gene MPL 
in ET and MF patients [48, 49] and most recently, two studies identified that the majority of 
patients with non-mutated JAK2 carry a mutation in the endoplasmic reticulum chaperone 
calreticulin (CALR) [50, 51].   A summary of the most frequently mutated genes is presented in 
Table 1. 
Despite sharing common genetic features, PV, ET and MF are classified as three distinct diseases 
with distinct clinical phenotypes (reviewed in [38]). Still they all share some clinical features, 
including a chronic course, the risk of major thrombotic events and the risk of transformation to 
acute leukemia. In particular, similar characteristics are observed in the early phase of disease, 
making them difficult to distinguish [52]. 
MPNs are a useful disease model to understand tumors since they arise form a single cell, readily 
permit clonal analysis and are chronic diseases, thus facilitating dissection of disease evolution. 
MPNs are not associated with a differentiation block and therefore permit studies of the earliest 
stages of malignancy that are inaccessible in other tissues. The discovery of JAK2V617F in 2005 
[42-45] has permitted research on the role of gene dosage [53], the role of JAK2V617F in 
hematological transformation [54] and the specific effect on mutant HSCs compared to their 
downstream progenitors [55].  
Molecular characterization of MPNs  
The mutational landscape of MPNs is increasingly well understood. The JAK2V617F mutation 
is the most prevalent mutation in MPNs and is present in the majority of PV patients (>95%) and 
in a significant proportion of ET and MF patients (50-60%) [42-45]. The kinase activity is 
dysregulated due to loss of the negative regulation of the pseudo-kinase (JH2) domain and leads 
to independence and/or hypersensitivity of hematopoietic cells to growth factors and cytokines 
[56]. JAK2V617F is present in cells of the hematopoietic compartment, but not in germline DNA 
[42-45] and serves as a powerful diagnostic tool to discriminate PV, ET and MF from reactive 
causes of erythrocytosis or thrombocytosis.  
Several additional mutations have been subsequently identified in MPNs including genes 
involved in cytokine signaling, splicing machinery, transcription factors, and epigenetic 
modifiers (reviewed in [57, 58]). Mutated genes that also target the JAK-STAT cytokine 
signaling pathway have been found in exon 12 of JAK2 and in myeloproliferative leukemia virus 
oncogene (MPL) and these are mutually exclusive with JAK2V617F. Co-occurring mutations 
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involved in the JAK-STAT pathway have also been identified, including loss of function 
mutations in the adaptor protein Sh2b3 (LNK), somatic mutations in suppressors of cytokine 
signaling (SOCSs) genes, and mutations in other negative regulators of cytokine signaling, 
including Casitas B-cell lymphoma (CBL) [59, 60]. RNA splicing mutations (including SF3B1, 
SRSF2 and U2AF1) [61], and transcription factor mutations (including IKZF1, FOXP1, ETV6, 
CUX1, NF-E2, RUNX1, and p53) have also been shown to have roles in MPN pathogenesis. The 
final class of mutations, suspected for their role in driving the clonal advantage in MPNs are 
those involving epigenetic regulation. Such epigenetic modifiers include TET2, IDH1/2, 
DNMT3A, ASXL1 and EZH2 [62].  
Disease progression, illustrated most clearly by transformation to AML, does not seem to be 
explained by individual genetic aberrations, although some mutated genes are frequently present 
in secondary AML (e.g., IDH1/2, TET2, ASXL1, LNK, TP53, EZH2, IKZF1 and RUNX1). 
However, in MF patients, only a handful of these mutations are associated with a poor prognosis, 
including IDH1/2, TET2, ASXL1, and TP53 [63-65]. These latter mutations are almost always 
detected in both the primary MPN and the secondary AML, with a prevalence of around 20%. 
Interestingly, the prevalence of ASXL1 represents 22% of MF patients, but only 5% in PV and 
ET patients [66]. The frequencies of TET2 and IDH1/2 mutations in secondary AML are around 
25% and 10% respectively [63] and an even higher frequency (45.5%) of TP53 mutations has 
been observed in post-MPN AML [67].  
Despite the discovery of this large range of mutations, about one third of ET and MF patients 
lacked an identifiable mutation. Recently, however, two groups discovered a somatic mutation in 
the endoplasmic reticulum chaperone CALR in the majority of JAK2 mutation negative patients 
[50, 51] and it was shown to be mutually exclusive with JAK2V617F and MPL. CALR-mutant 
ET and MF patients had a milder phenotype compared with JAK2V617F-mutant ET and MF 
patients and showed a significantly longer overall survival [50]. CALR can now be used as an 
additional diagnostic tool to discriminate several MPN subtypes [68], providing a diagnosis in 
patients previously difficult to classify.  
Such a finding has major implications for previous MPN research that has mostly focused on 
JAK2-mutant compared to JAK2-non-mutant patients. Such studies had not accounted for CALR 
status   and   many   “mutation   negative”   patients   are   likely   to   be   CALR   positive   and   these   old  
datasets could hold substantial new information (as performed recently by Rampal et al. [69]). 
Characterization of different MPN subtypes 
Despite this extensive molecular knowledge, it remains puzzling why this collection of mutations 
result in three distinct disease entities. Current approaches to classify MPN subtypes have also 
met with confusion for several reasons (Figure 1): first, MPN subtypes are diagnosed mainly 
based on binary decisions regarding values that are continuous (e.g., hemoglobin, hematocrit or 
red cell mass). This makes patients with borderline values difficult to diagnose as the disease 
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progresses and is further complicated by the fact that a raised hematocrit does not always predict 
an increased red cell mass and vice versa. This confusion is illustrated particularly well in 
patients who present with isolated thrombocytosis and increased bone marrow reticulin fibrosis. 
If these patients lack further ET or MF characteristics, they can be diagnosed with neither ET nor 
MF, although the clinical features of an MPN are clearly present [70].  
Second, the existence of three distinct disease entities could itself be questioned – is primary 
myelofibrosis (PMF) a separate disease when it could be viewed as an accelerated phase of 
previously undiagnosed ET or PV [38, 70, 71]? This concept is supported by the fact that PMF is 
clinically undistinguishable from post-ET MF and that the frequency of JAK2V617F, CALR, 
and MPL mutations is similar in ET and PMF. Also, patients that are diagnosed with PMF might 
have had thrombocytosis for many years before diagnosis. This has major implications for MPN 
diagnoses, since PV and ET could then be considered as chronic phase MPNs and MF as 
accelerated phase MPNs, preceded by another (undiagnosed) MPN [38].  
A third reason for confusion in our understanding of MPN classification is the large variability 
observed in disease phenotypes in mouse knock-in models (reviewed in [72, 73]. Heterozygous 
mouse JAK2V617F models show a PV-like phenotype [74-76] with wide variations in 
hematocrit, platelet and white blood cell values whilst a human V617F knock-in mouse model 
shows an ET-like phenotype where mice progress to PV or MF [77]. The effect on blood cell 
types produced is different among the four models, varying from a mild increase in some 
lineages [76, 77] to a more than 80-fold increase in erythroid and myeloid precursors [75]. Also, 
the effect on stem and progenitor cells is not consistent among these mouse models; some 
models show an increased primitive cell fraction [74, 78, 79] and other models show a decrease 
or no change in stem and progenitor cell fraction [55, 76, 77].  
Gene dosage 
Alongside the discovery of JAK2V617F, it was noted that while most MPN patients had cells 
with a heterozygous mutation, a small proportion, mostly PV patients, also possessed cells that 
were homozygous for JAK2V617F. Classically, loss of the wild-type allele in tumor-suppressors 
is a common mechanism of developing homozygosity; however, for JAK2V617F it typically 
results from acquired uniparental disomy (UPD). UPD is a mitotic recombination and 
duplication of the mutant allele, and the progression from a heterozygous to a homozygous state 
in MPNs occurs in the distal part of chromosome 9p (UPD9p) [44]. UPD was originally reported 
in 30% of PV patients but was rare in ET [42-45] and homozygous JAK2V617F erythroid clones 
were observed in PV patients, but rarely in ET patients [80]. These data suggested that gene 
dosage was an important distinguishing factor in different MPNs, whereby JAK2V617F 
homozygosity results in a PV phenotype. However, a recent study shows that homozygous 
clones are detectable in approximately 50% of the ET patients and are undetectable in some PV 
patients [53]. These discordant observations make it difficult to draw conclusions about the 
causal role of homozygosity of JAK2V617F in PV patients. Nevertheless, the expression of 
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mutant JAK2 at a specific level in various cell types seems to play a role in the different disease 
phenotypes [81], although gene dosage cannot be the sole contributor to the distinct disease 
phenotypes. 
Downstream JAK2 signaling 
The dysregulated kinase activity caused by the JAK2V617F mutation leads to independence 
and/or hypersensitivity of hematopoietic cells to growth factors and cytokines [56]. Several 
signaling cascades are activated as a result of mutated JAK2, including the STAT5, MAPK, RAS 
and PI3K pathways [43, 44, 82, 83]. In addition to gene dosage, these different signaling 
pathways could be another important player in driving phenotypically distinct disorders. 
A powerful approach to analyze distinct MPN phenotypes associated with JAK2V617F is to use 
clonally-derived cells from MPN patients and genotype for their individual JAK2 mutational 
status. This approach readily permits the identification of clones with distinct genotypes from 
within the same patient, thereby avoiding inter-individual variations. Using this approach, Chen 
et al. showed that heterozygous mutant erythroid colonies of PV and ET patients exhibit 
differences in their signaling pathway despite bearing the same single genetic lesion and 
specifically pointed toward a differential response to STAT1. This work showed that an ET-like 
phenotype was accompanied by an enhanced STAT1 activity that resulted in an increase of 
megakaryocytic differentiation and a repression of erythroid differentiation. Furthermore, 
inhibition of STAT1 activity with a dominant negative form of STAT1 (STAT1DN) in 
progenitor cells resulted in a switch to a PV-like phenotype with an increase of erythroid 
colonies. These results suggest that the disease phenotype of individual patients depends on a 
certain degree of intracellular STAT1 signaling [84]. 
The role of other signaling moieties downstream of JAK2 has also been examined in relation to 
JAK2V617F. One study demonstrated that JAK2V617F mutant cells co-expressing the EPO-
receptor lacked a STAT5 binding site and showed decreased malignant cell transformation and 
tumorigenesis [85] although the role of STAT5 in MPNs could not be totally clarified by this 
study. Subsequently, by crossing a JAK2V617F knock-in mouse strain with a STAT5 knock-out 
mouse strain, it was demonstrated that deletion of STAT5 could rescue the PV phenotype 
induced by JAK2V617F expression [86]. Replacing STAT5 expression by retroviral transduction 
and transplantation in a STAT5-deficient mouse resulted in a redevelopment of a PV phenotype 
and blood counts that were comparable to the JAK2V617F knock-in mouse with wild-type levels 
of STAT5. These results concluded that STAT5 is required for the pathogenesis of PV induced 
by JAK2V617F [86]. This was corroborated by work that showed JAK2V617F mice did not 
result a PV phenotype after deletion of STAT5 [87]. Together these data suggest that STAT5 




A final area of intense scrutiny is the role of interferon-alpha (IFN-α) which been used to treat 
MPNs for many years [88, 89] without a clear idea of the mechanism by which IFN-α operates. 
Recently, it was shown that in addition to achieving normalization of blood counts, IFN-α also 
reduced JAK2V617F allelic burden [90, 91] and activated the cell cycle machinery in quiescent 
mutant HSC populations [92, 93]. Work in JAK2V617F knock-in mouse models also supports 
the therapeutic potential of IFN-α, where the mutant stem and progenitor cells are killed more 
effectively than their wild-type counterparts [94, 95]. This will certainly be an area of great 
interest in years to come.  
Alternative theories for distinct MPN phenotypes  
In addition to gene dosage and downstream JAK2 signaling differences, other mechanisms have 
been suggested to play a role in distinct MPN phenotypes. One theory suggests a familial 
predisposition for the development of MPNs due to additional inherited alleles. Although most 
MPNs appear to be sporadic, familial MPNs have been widely described and are clinically 
similar to the sporadic type. In familial cases, JAK2V617F, MPL W515L/K and TET2 
inactivation are the most recurrent somatic mutations, and are present in combination with 
inherited MPN-predisposition alleles [96-98]. It has been demonstrated that JAK2V617F 
preferentially  appears  on  a  specific  JAK2  haplotype,  called  “46/1”  [99] and this appears to be the 
most important common risk factor for the acquisition of JAK2V617F, resulting in the 
development of MPNs. Two theories have been proposed to explain this observation; the 
“hypermutability   theory”   suggests   that   46/1   is   genetically  more   unstable   and   leads   to   a   faster  
mutation   acquisition   while   the   “fertile   ground   theory”   suggests   that   there   is   no   difference   in  
acquisition of JAK2V617F, but additional factors on the 46/1 haplotype provide a selective 
advantage to the JAK2 mutant clone [96].  
Another possible explanation for the phenotypic diversity observed amongst different MPN 
subtypes focuses on inherited modifiers in individual patients. Single nucleotide polymorphisms, 
or SNPs, have been analyzed in gene regions that are involved in the JAK-STAT pathway, 
including the genes JAK2, MPL, EPO-receptor (EPOR) and G-CSF-receptor (GCSFR), in large 
patient cohorts. These studies have identified specific SNPs in JAK2 and a single SNP in EPOR 
that are associated with PV but not with ET or MF suggesting that host genetic variation might 
lead to a specific disease phenotype [100]. 
Clonal evolution of MPNs 
The relationship between the JAK2V617F mutation and the clonal expansion of mutant cells that 
eventually results in an MPN is poorly understood. One certain requirement for all MPNs is that 
the initial clone must expand relative to other clones within a patient and generally this is thought 
to occur through the acquisition of a mutation or series of mutations in HSCs that give the 
mutant clone a self-renewal advantage over time. This process can eventually lead to monoclonal 
hematopoiesis, which is a well-documented phenomenon in hematological malignancies [66, 
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101]. The reduced clonal diversity with age may alter the competitive ability of endogenous 
HSCs, thereby permitting (or restricting) the expansion capabilities of a clone that acquires a 
JAK2 mutation. Importantly, the clonal evolution of MPNs sometimes involves the progression 
to a more advanced disease (e.g., JAK2V617F homozygosity, secondary MF, or AML). 
Expansion of homozygous clone 
Typically, JAK2V617F homozygosity has been regarded as a feature of PV, but recent evidence 
shows that JAK2V617F homozygosity occurs with similar frequencies in both PV and ET [53]. 
The prevalence and clonal relationship of homozygous mutant erythroid colonies can be 
determined by genotyping colonies from JAK2V617F-positive PV and ET patients. When this 
was performed, homozygous erythroid colonies could be identified in both ET and PV patient 
samples but the overt expansion of a dominant homozygous clone was only observed in PV. 
These data suggest the need for additional non-JAK2 mutations to drive disease progression, a 
hypothesis that is further supported by the observation in mouse models [55, 77, 81] and normal 
individuals [102, 103] that JAK2V617F alone is insufficient to cause clonal expansion and 
disease progression. In humans, this is illustrated by transplantation experiments showing that 
human cell engraftment in immunodeficient mice could not be achieved by primitive cells with a 
low burden of JAK2V617F. Furthermore, primitive cells from high burden PV patients that were 
capable of repopulating in xenograft experiments were not able to out-compete normal cells 
[104].  
Several lines of evidence suggest the presence of a pre-JAK2 event (reviewed in [98]). 
Clonogenic cytogenetic abnormalities have been observed in JAK2V617F positive MPNs, 
including the deletion of 20q, trisomy 8 and trisomy 9. Additionally, JAK2V617F-positive 
patients have developed JAK2V617F-negative AML [105, 106], which supposes the existence of 
a pre-existing clone that diverges into a JAK2-mutant and a JAK2 wild-type subclone, the latter 
of which acquires the leukemogenic event. However, no consensus exists about the molecular 
identity   of   the   “pre-JAK2-phase”,   and   this   is   further   confounded   by   inaccurate   JAK2  
quantification and X-chromosome inactivation patterns [105].  
Different roles in different cells 
Evidence is mounting that the JAK2V617F mutation affects HSCs differently than progenitors 
and mature cells [55, 79, 107]. This is perhaps best understood by asking what the impact of 
increasing proliferation would be on a cell population that often divides (progenitor cells) 
compared to its impact on a cell population that is largely quiescent (HSCs). In the mouse, long 
term HSCs are estimated to divide just five times throughout adult life and their cell biology (and 
maintenance of self-renewal) is adapted to this frequency of cell division [108]. Indeed, recent 
evidence in single cell assays suggests that HSC self-renewal capacity is negatively impacted by 




In MPN patients, the JAK2V617F mutation is more prevalent in granulocytes compared to a 
small minority of primitive cells, especially in PV and ET patients [109-112]. HSCs from MF 
patients, on the other hand, show a higher JAK2V617F mutation frequency [110]. This is 
mirrored in patients with CML, where HSC self-renewal ability is compromised [113] and BCR-
ABL is only is expressed in a small proportion of primitive cells [114, 115]. This suggests that 
chronic phase disease is the result of progenitor cells that are benefitting from the proliferation 
advantage (and causing disease), while HSCs themselves are not benefitting.  
Moving forward, therefore, it is critical to undertake studies of stem and progenitor cells in 
purified fractions. Studies which assess lin-Sca-1+c-Kit+ (LSK) cells in mouse models or 
CD34+CD38– cells in patients must be recognized as assays of progenitor cells (and not HSCs) 
since these populations are dominated by progenitor cells. In order to study the impact of 
individual mutations on HSCs and the implications for establishment, maintenance and 
expansion of a clonal population, it is therefore crucial to assess this in highly purified 
populations. 
JAK2V617F and HSC biology  
Clonal expansion can only occur when a clone has a survival and/or proliferation advantage 
compared to other clones in the organism. In malignancies, acquisition of such a clonal 
advantage is critical for tumor establishment and disease progression. In MPNs, clonal expansion 
(or lack thereof) is especially interesting at the HSC level, since the balance of self-renewal and 
differentiation could be used as a therapeutic target similar to successful studies using all-trans-
retinoic acid (ATRA) in acute promyelocytic leukemia (reviewed in [116]) 
Along these lines, treatment with IFN-α in knock-in mouse models has recently been 
demonstrated to specifically deplete JAK2V617F propagating cells, leading to cell cycle 
activation of long-term mutant HSCs [94, 95]. Also, recent evidence has suggested that the 
MPN-associated adaptor molecule LNK modulates the homeostatic regulation of HSCs [117]. A 
complete understanding of how the clonal advantage is established and maintained could reveal 
additional information about the key mechanisms driving the clonal evolution of MPNs. If the 
establishment of an advantageous clone can be mapped out step by step, therapies could be tested 
at each stage of the process.  
Mouse models are useful to examine relative self-renewal capacity in mutant HSCs since these 
cells can be isolated at high purities and are from a defined genetic background. Several 
JAK2V617F knock-in mouse models have been developed, although the effect on stem and 
progenitor cells is not entirely consistent among these mouse models (reviewed in [72, 73]). 
Serial competitive transplantation experiments are the gold standard for testing relative stem cell 
activity and these experiments are ideally carried out using age and sex-matched wild-type 
littermate controls. To formally demonstrate a self-renewal advantage (and thereby infer a clonal 
advantage over non-mutant HSCs in MPN patients), secondary transplantation experiments must 
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be carried out. One knock-in model [74] shows a PV-like phenotype with expansion of 
phenotypically defined stem and progenitor cells in the bone marrow and spleen. In primary 
transplantation experiments using a 75:25 ratio of heterozygous mutant:WT cells, this same 
model did not display a strong HSC advantage since donor chimerism in recipients was observed 
at a 70:30 ratio [118]. Another mouse knock-in model [76, 79] demonstrated that JAK2V617F 
disease initiating cells are predominantly long-term HSCs and achieve clonal advantage during 
disease progression. Intriguingly though, when secondary transplantation experiments were 
performed in this model there was no HSC advantage observed [76]. Similarly, another knock-in 
model [94] described an increased production of mutant HSCs in primary transplantations that 
was not mirrored in secondary transplantations. The knock-in models produced by Li et al., 
using a human JAK2V617F displayed a mild HSC defect in the heterozygous mouse that was 
more marked in secondary transplantations [55, 77] and a severe defect in JAK2V617F 
homozygous mice in primary and secondary transplantations [55, 77, 81].  
A proposed model of selective pressure 
Most evidence suggests that JAK2V617F does not, on its own, confer a strong HSC self-renewal 
advantage and disease heterogeneity amongst JAK2 mutant patients is substantial. The easiest 
explanation for such differences would be the acquisition of specific mutations for specific 
disease etiologies, however, the cataloguing exercise in several large genomic studies has yet to 
identify ET-specific or PV-specific collaborators alongside JAK2V617F. We therefore propose 
that selective pressure to obtain a self-renewal advantage that is imposed on the initiating 
JAK2V617F-positive clone results in stem and progenitor cell heterogeneity that eventually 
manifests as disease heterogeneity (Figure 2). In this model, a single cell acquires the 
JAK2V617F mutation and its consequent proliferation advantage creates a clone that grows 
rapidly, but lacks a long-term self-renewal advantage. Each and every cell of the clone would 
then be subjected to selective pressure to acquire a self-renewal advantage due to the increased 
replicative stress. The clone of cells bearing the JAK2V617F mutation would proliferate and 
differentiate, creating a large population of heterogeneous target cells for additional mutations. 
The lineage biases (e.g., platelets or erythrocytes) displayed by the distinct disease subtypes 
would then be derived from the intrinsic bias of the cell that acquires the self-renewal advantage 
(i.e., the target cell defines the disease). In this manner, it would be possible to develop diverse 
phenotypes from similar starting cell populations that evolve differently prior to acquiring a 
clonal advantage. These possibilities should be testable in mouse knock-in models, assessing 
both the impact of single mutations as well as the combinatorial effect of double or triple mutant 
stem and progenitor cells. 
Conclusion and future directions  
Much work has been undertaken to further understand the molecular mechanisms that drive 
MPN pathogenesis. Characterization of the distinct disease subtypes, genetic events leading to 
malignant transformation, and the individual behavior of mutant HSCs are areas of current 
13 
 
interest. The mutational landscape has essentially been established, but the task of understanding 
the individual and combinatorial contributions of each mutation is in its infancy. Existing data on 
MPNs should be reconsidered based on the complete genetic landscape to re-assess questions 
about  different  MPN  subtypes  and  to  understand  “low”  versus  “high”  burden  disease.  Individual  
mutations should be related to disease phenotype, prognosis, and therapeutic effects. Of 
particular importance is for old studies of JAK2V617F-negative MPNs to be viewed through the 
lens  of  CALR  mutations,   since   a   substantial   portion  of   “negative”  patients  would  high  burden  
CALR mutant patients. This should allow categorization of disease into low and high clonal 
burden disease and give insight into the biology driving clonal expansion. 
Despite the discovery of JAK2V617F almost a decade ago, there exists no good explanation for 
how distinct disease entities arise as the result of a single genetic aberration. Moreover, it is 
unclear how the recently discovered mutations in CALR result in similar disease phenotypes as 
MPNs bearing the JAK2V617F mutation. As a result, diagnosing MPN patients can be difficult; 
especially in the case of patients with borderline blood values. The accurate characterization of 
MPN subtypes will lead to a more appropriate and more personalized treatment of MPN patients.  
Another difficulty in treating MPN patients is that while current therapies can slow down the 
extensive cell production, the disease itself remains uncured. One theory suggests that mutant 
tumor stem cells are not susceptible to current therapies and as a result, the disease causing cells 
remain capable of forming a new advantageous mutant clone, leading to eventual relapse. The 
composition of these newly formed clones could differ to the original clone and result in therapy 
resistance [119]. 
Much work remains to fully understand disease differences and the mechanisms that are 
involved in hematological transformation (e.g., to secondary MF or AML). While numerous 
mutations in the JAK-STAT signaling pathway are mutually exclusive and most common in 
chronic phase MPNs, co-occurring mutations (ASXL1 and TET2) with suspected roles in clonal 
expansion have also been identified. The exact role of these genetic aberrations in relation to 
disease phenotypes is still unclear, although ASXL1 mutations have been associated with MF [63, 
120]. With the vast majority of these mutations now identified, future efforts should be focused 
on relating these mutations to pathogenic mechanisms, clinical outcome and prognosis.  
A final field of interest in MPN research is the cellular process underlying disease progression. 
Obtaining a specific proliferation and/or survival advantage is critical for tumor establishment 
and disease progression. The mechanism of acquiring a clonal advantage at the HSC level, 
however, is still poorly understood. Furthermore, once such an advantage is obtained, HSCs and 
their progeny are differently affected. For example, activating tyrosine kinase mutations on 
HSCs appears to negatively affect the self-renewal machinery but improve the differentiation and 
proliferation potential of HSCs [55, 113, 121, 122]. The effect of such mutations in progenitor 
and mature cells, on the other hand, is largely beneficial, as exemplified by JAK2V617F. This 
has major implications for disease initiation, especially if the proposed model of selective 
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pressure is correct whereby the heterogeneous cell population created as a result of the first 
mutation will determine eventual disease subtype based on the lineage biases and differentiation 
state of the cell that eventually acquires the self-renewal advantage. 
In conclusion, while the search for distinguishing factors between PV, ET and MF should be 
continued, this should be largely achievable by focusing on the relationship of currently 
discovered mutations and the clinical outcome and prognosis of patients bearing these genetic 
lesions. Understanding the evolution of disease and the individual burden of each mutation will 
help to expand our capacity to diagnose MPNs more correctly and, eventually to identify more 
specialized therapies. A good starting point would be to reconsider the vast amount of existing 
data in the context of the complete molecular landscape of disease with ultimate goal to track 
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Figure$1.$Classiﬁca)
on$of$M
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$subtypes.$It!rem
ains!unclear!w
hy!one!m
uta9on!is!associated!w
ith!three!dis9nct!disease!en99es.!Since!diagnosing!M
PN
!pa9ents!is!
based!on!binary!decisions!of!con9nuous!variables!(e.g.,!platelet!count)!at!single!9m
e!points,!pa9ents!w
ith!borderline!values!are!diﬃ
cult!to!classify.!M
oreover,!
prim
ary!M
F!m
ay!in!fact!represent!the!presenta9on!of!the!accelerated!phase!of!PV!or!ET.!D
ecisions!are!further!com
plicated!by!addi9onal!factors!that!could!alter!
presenta9on!(e.g.,!gene!dosage,!STAT!signaling,!the!role!of!IFN
*α,!fam
ilial!predisposi9on!and!host!gene9c!varia9on).!This!variability!is!further!illustrated!by!the!
diverse!phenotypes!observed!in!diﬀerent!m
ouse!m
odels!of!JA
K2V617F..!!
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Figure$2.$Clonal$evolu)
on$in$M
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al!steady!state:!O
n!average,!for!every!non*m
utant!H
SC!w
hich!divides,!one!daughter!cell!retains!H
SC!poten9al.!
Throughout!the!life!of!the!organism
,!the!H
SC!num
ber!rem
ains!approxim
ately!constant!B)!A
!JA
K2V617F!m
utant!H
SC!divides!m
ore!frequently.!Since!the!V617F!
m
uta9on!does!not!confer!increased!H
SC!self*renew
al,!H
SC!num
bers!w
ill!not!increase,!how
ever,!each!H
SC!w
ill!generate!m
ore!progenitors!w
hich!w
ill!also!divide!m
ore!
frequently.!Both!H
SCs!and!progenitors,!therefore!w
ill!undergo!addi9onal!replica9ve!stress.!Consequent!selec9on!pressure!to!acquire!a!clonal!advantage!results!in!
one!of!the!heterogeneous!popula9on!of!cells!acquiring!an!addi9onal!m
uta9on!that!drives!higher!survival!and/or!self*renew
al.!The!cell!that!acquires!this!m
uta9on!
need!not!be!an!H
SC,!but!rather!could!be!any!num
ber!of!JA
K2V617F!m
utant!stem
/progenitor!cells!and!the!target!cell!of!the!second!m
uta9on!could!therefore!
determ
ine!the!disease!phenotype.!
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